FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC

The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news